Biospectator Reporter Seo Yoon-seok
Ildong Shionogi Development ‘Xocova (S-217622)’
Ildong Pharmaceutical announced on the 4th that it has applied for item permission for ‘Xocova (ensitrelvir fumaric acid, S-217622)’, an oral COVID-19 treatment candidate, to the Ministry of Food and Drug Safety in Korea.
Developed by Japan’s Shionogi, Zokoba has the exclusive right to develop and commercialize in Asia (excluding Japan) by Hong Kong’s Ping An Shionogi. In September of last year, Ildong Pharmaceutical signed a license agreement with Ping Anshionogi in Hong Kong for domestic distribution rights.
According to the announcement, the application for permission included the results of clinical trials conducted by Ildong Pharmaceutical in Korea and the results of phase 2/3 clinical trials conducted by Japan’s Shionogi in Asia.
According to Ildong Pharmaceutical, Jocoba conducted a clinical trial (phase 2/3, phase 3) during the epidemic of the Omicron mutant virus and tested five major symptoms (cough, sore throat, sore throat, sore throat, It was emphasized that it is a drug that has been confirmed to have an antiviral effect in the body as well as improvement in runny nose and nasal congestion, fever, and fatigue.
Zokova is an oral antiviral drug that is taken once a day for 5 days and is a drug with a mechanism that selectively inhibits 3CL-protease to prevent the SARS-CoV-2 virus that causes COVID-19 infection from multiplying in the body.
Zokova received emergency use approval from Japan’s Ministry of Health, Labor and Welfare (MHLW) in November last year and is currently being prescribed in Japan. The Japanese government has so far secured a total of 2 million worth of Jokoba and is expanding its use to respond to Corona 19.
An official from Ildong Pharmaceutical said, “Zokoba has clinical data accumulated during the Omicron mutation epidemic, and it can be a useful option for COVID-19 treatment because of its wide prescription range and convenient dosage method.” We will actively cooperate with the screening process.”
